Evidence map›Paper›PMID 31363497›Full record

ArticleWellcome open research2019

ZMYM2 inhibits NANOG-mediated reprogramming.

Moyra Lawrence, Thorold W Theunissen, Patrick Lombard, David J Adams, José C R Silva

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Human iPS Cells for Clinical Applications and Cellular Products.Handbook of experimental pharmacology · 2023
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Moyra LawrenceWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 1QR, UK.ORCID https://orcid.org/0000-0001-9386-5633
Thorold W TheunissenWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 1QR, UK.
Patrick LombardWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 1QR, UK.
David J AdamsExperimental Cancer Genetics, Wellcome Sanger Institute, Cambridge, CB10 1SA, UK.ORCID https://orcid.org/0000-0001-9490-0306
José C R SilvaWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 1QR, UK.ORCID https://orcid.org/0000-0001-5487-1117
Wellcome/MRC Cambridge Stem Cell Institute · GBWashington University in St. Louis · USWellcome Sanger Institute · GB

Funding

Medical Research Council MC_PC_12009Medical Research Council MR/R017735/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

differentiationNanogpluripotencyreprogrammingZinc finger protein

Identifiers

PMID31363497
PMCPMC6640293
OpenAlexW2948519940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.